Issue #5 October 2020 • 2 minute read

Welcome to VITALITY.

You’re receiving this newsletter because you’re a customer, partner, or you’ve otherwise subscribed or opted in at one of our events, conferences, or website


  • Letter from CEO, Craig Cooper.
  • New smartwatch partnership with Google-backed Mobvoi.
  • EU Patent Granted.
  • Upcoming and recent events.
  • Quarterly clinical research update.

From the Heart

Thoughts from our CEO, Craig Cooper


COVID-19 forced us to transform how we engage with our friends, extended families, and customers. Like broader shifts such as working from home, telemedicine and remote monitoring happening around the world, we are reimagining how we can support our customers and partners with the timely information they need.

In this vein, we are excited to introduce several new resources including a quarterly research update highlighting studies of significance, and a webinar that we are co-hosting on Tuesday, November 17. Managing Ischemia with Nonobstructive Coronary Arteries (INOCA) will feature leading cardiologists from Johns Hopkins, Baylor and the University of Arizona. Click here to register.

We hope you can join us to learn more about our gold-standard SphygmoCor® technology for measuring central blood pressure, arterial stiffness, and other vital cardiovascular parameters.

Stay healthy, stay strong,


Partnership with Mobvoi on New Smartwatch


For many of us, glancing at our fitness trackers and smartwatches throughout the day is second nature. But we may not be getting the most impactful data needed to improve our health. To solve this, CardieX has partnered with leading consumer electronics and AI company, Mobvoi, to showcase our Arty™ health analytics platform built on our proprietary and globally patented SphygmoCor® technology. Learn more here.

European Patent Granted for Brachial Cuff Blood Pressure Technology


ATCOR was recently granted a new patent by the European Patent Office for the Company’s proprietary SphygmoCor® technology used in cuff-based blood pressure devices. The patent (EP2566387) for non-invasively estimating the heart’s pressure and pressure waveform related to cardiac function and arterial properties using a conventional BP cuff inflated to low pressure, builds on past patents granted in the United States and Japan and demonstrates its unique nature. Read more.

Upcoming and Recent Events


We hope you can join us for a webinar next month, Managing Ischemia with Nonobstructive Coronary Arteries (INOCA) Webinar (November 17, 5pm – 6pm CT). Moderated by Sachin Shah, MD, our panel of experts will explore the issue of Ischemia with Non-Obstructive Coronary Arteries (INOCA) and the unique role central blood pressure measurement and Enhanced External Counterpulsation (EECP) has in diagnosis and care. Click here to register.

Our speakers:


image China International Medical Equipment Fair
Thank you to everyone who attended our educational sessions and stopped by our booth October 19 – 22 at the China International Medical Equipment Fair (CMEF) in Shanghai!

Quarterly Clinical Research Update


To highlight significant new research, we have started a quarterly round-up of clinical studies at the intersection of arterial health, renal disease and cardiovascular health – including a single page summary slide that can be downloaded to use in your own presentations. Click on the study titles below to download slides.

To sign up for future Research Updates, click here.

Get In Touch


We’d love to hear from you

About Us

ATCOR is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR·X brand, the company also develops and licenses physiological and health analytics for wearable devices for medical and consumer applications. The company’s digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients’ health (2021 launch). ATCOR is a subsidiary of CardieX Limited, which is listed on the Australian Stock Exchange (ASX:CDX).